The World Health Organisation has issued an updated guideline on the management of Multi-system Inflammatory Syndrome in Children associated with COVID-19.
The world health governing body, on its website on Tuesday, said Multi-system Inflammatory Syndrome in Children associated with COVID-19 was a rare but serious condition where children with COVID-19 developed inflammation affecting different organs of the body.
The WHO said, “Children with this condition need specialised care and may need to be admitted to intensive care.
“Although MIS-C is a serious condition, with the right medical care, children with this condition recover.”
It also noted that WHO’s updated guidelines recommended use of corticosteroids in hospitalised children (aged 0-18 years) with this condition in addition to supportive treatment and care.
Corticosteroids are a class of medication intended to lower inflammation of the body.
According to the statement on the WHO website, this recommendation follows the availability of three observational studies, pooling data from a total of 885 patients.
“WHO first described this condition in May 2020, and provided a preliminary clinical definition.
“Overall, children remain at a low risk of developing severe or critical COVID-19, but similar to adults, certain underlying conditions make children more susceptible to severe disease,’’ it stated.
The statement added that the most commonly reported of these conditions were obesity, chronic lung disease (including asthma), cardiovascular disease and immunosuppression.